Thus, the exact level of Src expression in a given cancer could offer a potential explanation for the inconsistent results of Dasatinib or other Src inhibitors in clinical trials; treatment of high-Src cancers would actually increase Stat3 activity, leading to metastasis. The gene discussed is STAT3; the disease is cancer.